News | March 24, 2025
AstraZeneca to invest $2.5 billion in new global strategic R&D centre in China
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
This aims to benefit approximately 4.5 crore families with six crore senior citizens with Rs. 5 lakh free health insurance cover on a family basis
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Department presents a detailed overview of the Pharma and MediTechsector and gives a detailed presentation on the activities of Department
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Subscribe To Our Newsletter & Stay Updated
